Table 3 |
|||
|
Results of ELISA using PM1-α peptide with polymyositis/scleroderma and various control sera |
|||
| Number (%) of anti-PM1-α-positive sera |
Mean value/standard deviation |
Top value |
|
|
|
|||
| Polymyositis/scleroderma (n = 40) |
22 (55) |
3.1/3.2 |
11.6 |
| Rheumatic disease controls (n = 452) |
33 (7.3) |
0.6/0.9 |
7.7 |
| Polymyositis (n = 40) |
3 (7.5) |
1.0/1.1 |
7.4 |
| Scleroderma (n = 205) |
27 (13.2) |
0.9/1.2 |
7.5 |
| Rheumatoid arthritis (n = 69) |
0 (0) |
0.3/0.2 |
1.1 |
| Mixed connective tissue disease (n = 6) |
0 (0) |
0.4/0.1 |
0.6 |
| Undifferentiated connective tissue disease (n = 10) |
0 (0) |
0.3/0.0 |
0.4 |
| Systemic lupus erythematosus (n = 114) |
3 (2.6) |
0.5/0.7 |
7.7 |
| Other rheumatic diseases (n = 8) |
0 (0) |
0.3/0.1 |
0.6 |
| Hepatitis C virus (n = 48) |
2 (4.2) |
0.5/0.5 |
2.6 |
| Organ specific disorders (n = 23) |
0 (0) |
0.4/0.2 |
0.8 |
| Hashimoto thyroiditis (n = 11) |
0 (0) |
0.3/0.2 |
0.8 |
| Grave's disease (n = 12) |
0 (0) |
0.4/0.2 |
0.8 |
| Healthy individuals (n = 4) |
0 (0) |
0.6/0.2 |
0.7 |
|
|
|||
|
Mahler et al. Arthritis Research & Therapy 2005 7:R704 doi:10.1186/ar1729 |
|||
